TRPV4 and influenza: Collectively, the data confirm that glecaprevir and everolimus significantly improved the increased inflammatory response following viral infection as well as the expression of viral proteins, providing strong evidence for further exploration of the function of TRPV4 during the replication of the H1N1 virus and as a potential anti-influenza drug target.